Michel Boiron 1925-2018

It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).

Read more

EHA first-ever CMML guidelines, now available

EHA 03

Joint recommendations on diagnosis and treatment of CMML from two European specialty societies were published the December issue in HemaSphere, the official journal of the European Hematology Association (EHA).

Read more

EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe

Mailing Headers EHA EBMT CAR T Cell Meeting 16

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders i...

lancet

Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

AdobeStock 71232722

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates am...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the...

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma ...

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic...

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a ...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic ...

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will...

Read more